At Forendo, we are pioneering the translation of intracrinology science into first-in-class therapeutic solutions. Intracrinology enables us to address diseases on an unprecedented tissue specific level. Our lead clinical compound in endometriosis addresses a significant unmet need through its local effect on endometriotic lesions. Our second program is targeting polycystic ovarian syndrome (PCOS) which has no approved therapies. In addition to women’s health programs, Forendo has a strategic collaboration with Novartis leveraging our unique HSD17B platform in chronic liver diseases. We are based in Finland and backed by leading life science investors.